- Home
- BTAI vs CDIO Comparison
BTAI vs CDIO Comparison
Compare BTAI & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- CDIO
- Stock Information
- Founded
- BTAI 2017
- CDIO 2017
- Country
- BTAI United States
- CDIO United States
- Employees
- BTAI N/A
- CDIO N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- BTAI Health Care
- CDIO Health Care
- Exchange
- BTAI Nasdaq
- CDIO Nasdaq
- Market Cap
- BTAI 8.3M
- CDIO 7.9M
- IPO Year
- BTAI 2018
- CDIO N/A
- Fundamental
- Price
- BTAI $1.84
- CDIO $3.44
- Analyst Decision
- BTAI Buy
- CDIO Buy
- Analyst Count
- BTAI 5
- CDIO 1
- Target Price
- BTAI $34.60
- CDIO $60.00
- AVG Volume (30 Days)
- BTAI 294.8K
- CDIO 57.8K
- Earning Date
- BTAI 08-05-2025
- CDIO 08-11-2025
- Dividend Yield
- BTAI N/A
- CDIO N/A
- EPS Growth
- BTAI N/A
- CDIO N/A
- EPS
- BTAI N/A
- CDIO N/A
- Revenue
- BTAI $1,852,000.00
- CDIO $19,902.00
- Revenue This Year
- BTAI $5.03
- CDIO $1,434.82
- Revenue Next Year
- BTAI $291.01
- CDIO $4,661.91
- P/E Ratio
- BTAI N/A
- CDIO N/A
- Revenue Growth
- BTAI 5.47
- CDIO N/A
- 52 Week Low
- BTAI $1.17
- CDIO $3.22
- 52 Week High
- BTAI $23.04
- CDIO $53.10
- Technical
- Relative Strength Index (RSI)
- BTAI 62.90
- CDIO 32.36
- Support Level
- BTAI $1.59
- CDIO $3.65
- Resistance Level
- BTAI $2.22
- CDIO $4.18
- Average True Range (ATR)
- BTAI 0.21
- CDIO 0.31
- MACD
- BTAI 0.04
- CDIO 0.12
- Stochastic Oscillator
- BTAI 75.00
- CDIO 4.49
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.